Affiliation:
1. University of Virginia
2. Isabela State University
Abstract
Abstract
Background: Children aged 5-14 years who are household contacts of index pulmonary TB cases have limited coverage for TB preventive therapy (TPT) due to variable uptake of the national guideline recommendations in the Philippines. We conducted a cost effectiveness analysis evaluating the expansion of latent TB testing and treatment among pediatric (5-14 years) household contacts of index TB patients in the Philippines.
Methods: Using a Markov state transition model, eligible household contacts (HHCs) age 5-14 years are screened for latent TB infection (LTBI) with either the tuberculin skin test (TST) or interferon gamma release assay (IGRA). Those who test positive are then simulated to receive one of the following TPT strategies: 6 months of daily isoniazid (6H), 3 months of weekly isoniazid and rifapentine (3HP), 3 months of daily isoniazid plus rifampicin (3HR) and the current practice of no testing or treatment for LTBI (NTT). The analysis assesses the projected cost and quality-adjusted life years (QALY) gained for every strategy from the perspective of the Philippines public healthcare system over a time horizon of 20 years. The total cost and gain in QALYs are presented as an incremental cost-effectiveness ratio (ICER) comparing cost per QALY gained for each strategy over NTT.
Results: Our model estimates that expanding TPT coverage to HHCs aged 5-14 years would be cost effective with incremental cost-effectiveness ratios (ICERs) ranging from 1,024 $/QALY gained when using TST and 6H (Uncertainty range: 497 - 2,334) to 2,293 $/QALY gained when IGRA and 3HR are used (Uncertainty range: 1,140 – 5,203). IGRA cost would have to drop to $5.50 to achieve similar results to strategies using TST. These findings were robust to sensitivity analyses over a wide range of parameter values.
Conclusion: Expanding TPT coverage to HHCs aged 5-14 years is cost effective when using TST and 6H closely followed by a strategy combining TST and 3HP. IGRA cost will require significant reduction to achieve results similar to TST.
Publisher
Research Square Platform LLC
Reference41 articles.
1. World Health Organization. Tuberculosis 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
2. United Nations Statistics Division. Global Sustained Development Goals Indicator Platform [Available from: https://unstats-undesa.opendata.arcgis.com/.
3. World Health Organization. WHO Operational Handbook on Tuberculosis. Module 1: Prevention - Tuberculosis Preventive Treatment 2020 [Available from: https://www.who.int/publications/i/item/9789240002906.
4. World Health Organization, UNICEF, United States Center for Disease Control. Stop TB, Partnership. United States Agency for International Development. Roadmap for Childhood Tuberculosis: Towards Zero Deaths Geneva, Switzerland2013 [Available from: https://apps.who.int/iris/bitstream/handle/10665/89506/9789241506137_eng.pdf.
5. The Philippines National Tuberculosis Program. TB Dashboard [Available from: http://racetb.doh.gov.ph/#!/layouts/dashboard-fullview.html.